Technology | 2019.11.08
Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs
OXFORD, United Kingdom, Nov. 8, 2019 /PRNewswire/ -- Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, today announced that data yielded by application of its 3D...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]ibitor-programs-300954931.html
